Condition

Refractory Multiple Myeloma clinical trials and research

• 25Clinical trials
• 5NIH research projects
• 3Countries

Newest Refractory Multiple Myeloma clinical trials

All recruiting trials (25)

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

• Cognitive training to help brain function in people getting CAR-T therapy for relapsed or refractory blood cancers

  A brain-training program given before and after CAR-T therapy is tested to see if it helps cognitive and neurological outcomes for adults with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07609030

• Selinexor with Carfilzomib, Isatuximab and Dexamethasone for relapsed or refractory multiple myeloma

  This trial tests whether a four-drug combination can help adults with relapsed or refractory multiple myeloma when they've had at least one prior treatment.

  Recruiting Phase 1/2 Hoosier Cancer Research Network · Madison, Wisconsin · NCT07479979

• Teclistamab plus pomalidomide vs standard therapy for relapsed multiple myeloma

  This study tests whether the combination of teclistamab and pomalidomide can work better than the usual regimen (carfilzomib, pomalidomide, and dexamethasone) for adults whose multiple myeloma has returned after some improvement.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Duarte, California · NCT07463807

• DC/MM fusion vaccine plus BCMA CAR-T for relapsed or refractory multiple myeloma

  This trial will test whether adding a personalized DC/MM fusion vaccine (with GM‑CSF) to standard BCMA CAR‑T therapy helps people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07377435

• FT836 CAR T-cell Therapy with Daratumumab in relapsed/refractory multiple myeloma

  This phase 1 study tests whether FT836 CAR T cells given with daratumumab are safe and show early signs of activity in adults with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07221032

• Response-based lowering of linvoseltamab doses for relapsed or refractory multiple myeloma

  This trial tests whether lowering linvoseltamab doses for people with relapsed or refractory multiple myeloma can control the cancer while reducing side effects.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07181941

• Talquetamab bridging therapy followed by ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

  This trial tests whether giving talquetamab as a temporary bridging treatment before cilta‑cel is safe and feasible for people with relapsed or refractory multiple myeloma who plan to receive CAR‑T therapy.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07093554

• Daratumumab‑hyaluronidase plus teclistamab vs standard daratumumab combinations for high‑risk relapsed or refractory multiple myeloma

  This phase 2 trial tests whether combining daratumumab with teclistamab helps people with high‑risk myeloma that has not responded to treatment or has come back, compared to usual daratumumab‑based therapies.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Coeur d'Alene, Idaho and 31 other locations · NCT06948084

• Dasatinib and quercetin plus preparation chemotherapy before CAR-T for relapsed or refractory multiple myeloma

  This phase II test will see whether adding dasatinib and quercetin to preparation chemotherapy and CAR-T cell therapy helps people with relapsed or refractory multiple myeloma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT06940297

• Personalized dendritic cell–myeloma fusion vaccine combined with elranatamab for relapsed or refractory multiple myeloma

  This will try a personalized dendritic cell–myeloma fusion vaccine given with elranatamab in people with relapsed or refractory multiple myeloma.

  Recruiting at 2 sites Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts and 1 other locations · NCT06799026

• Treatment for relapsed or refractory multiple myeloma with extramedullary disease

  This study is testing a new combination of medications to see if it can help people with relapsed or hard-to-treat multiple myeloma that has spread outside the bone marrow.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT06627751

• Combining SX-682 with standard treatments for relapsed or refractory multiple myeloma

  This study is testing if adding a new drug called SX-682 to standard treatments can help people with relapsed or refractory multiple myeloma feel better and fight their cancer more effectively.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT06622005

• Combining Elotuzumab and Iberdomide with Dexamethasone for Relapsed Multiple Myeloma

  This study is testing a new combination of Elotuzumab, Iberdomide, and Dexamethasone to see if it helps people with relapsed multiple myeloma who have already tried another treatment.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06518551

• Testing a new combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of two treatments, iberdomide and teclistamab, to see if they can help people with relapsed or refractory multiple myeloma feel better and fight their cancer more effectively.

  Recruiting at 16 sites Phase 1 National Cancer Institute (NCI) · Phoenix, Arizona and 16 other locations · NCT06465316

• Assessing a new treatment for relapsed and refractory multiple myeloma

  This study is testing a new treatment called OPN-6602, alone and with another medication, to see if it can help people with relapsed or hard-to-treat multiple myeloma feel better and stay safe during the process.

  Recruiting at 12 sites Phase 1 Opna Bio LLC · Gilbert, Arizona and 11 other locations · NCT06433947

• Outpatient treatment with elranatamab for relapsed multiple myeloma

  This study is testing a new treatment called elranatamab for people with relapsed multiple myeloma to see if it can be safely given at home and help improve their health without needing to stay in the hospital.

  Recruiting at 6 sites Phase 2 Ontario Clinical Oncology Group (OCOG) · Vancouver, British Columbia and 5 other locations · NCT06421675

• Talquetamab combined with iberdomide and dexamethasone for relapsed or refractory multiple myeloma

  This phase 1 trial will test whether adding iberdomide and dexamethasone to talquetamab helps people with relapsed or refractory multiple myeloma who have already received proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06348108

• Using elranatamab to treat relapsed/refractory multiple myeloma

  This study is testing if a new drug called elranatamab can help people with tough-to-treat multiple myeloma feel better and keep their disease from getting worse.

  Recruiting at 3 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT06138275

• IDP-023 treatment for advanced blood cancers

  This study is testing a new treatment called IDP-023, which uses special immune cells alone and with other medications to see if it can help people with advanced blood cancers like multiple myeloma and non-Hodgkin lymphoma.

  Recruiting at 9 sites Phase 1/2 Indapta Therapeutics, INC. · Los Angeles, California and 11 other locations · NCT06119685

• Isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone combination for relapsed/refractory multiple myeloma

  This trial tries the combination of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone to see if it can reduce multiple myeloma in adults whose disease has returned or stopped responding to prior treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT05922501

• Combination therapy for relapsed or refractory multiple myeloma

  This study is testing a new combination of medications to see if it can help people with relapsed or refractory multiple myeloma feel better and improve their treatment results.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT05896228

• Testing different doses and schedules of belantamab mafodotin for treating tough cases of multiple myeloma

  This study is testing different doses and schedules of a new cancer treatment called belantamab mafodotin to see if it helps people with tough cases of multiple myeloma feel better and live longer.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT05847569

• Evaluating patient experiences with isatuximab for multiple myeloma

  This study is trying to learn about the experiences of adults with relapsed or refractory multiple myeloma who are receiving isatuximab, by using digital health tools to see how the treatment affects their daily lives over three months.

  Recruiting Pack Health · Houston, Texas and 1 other locations · NCT05053607

• Dual-target BCMA–CD19 CAR T-cell therapy for relapsed or refractory multiple myeloma and plasmacytoid lymphoma

  This treatment will try a dual-target CAR T-cell therapy that attacks BCMA and CD19 in people with relapsed or refractory multiple myeloma or plasmacytoid lymphoma who have exhausted standard options.

  Recruiting at 2 sites Phase 1 iCell Gene Therapeutics · Shenzhen, Guangdong and 1 other locations · NCT04162353

NIH-funded research (5)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• New targeted treatment for relapsed multiple myeloma

  A new drug called KS100 aims to block ALDH enzymes to kill treatment-resistant myeloma cells in people whose disease has returned.

  NIH research Rowan University · Glassboro, United States · NIH-11324662

• How the protein ULK3 affects treatment‑sensitive and treatment‑resistant multiple myeloma

  This project tries new drugs that block ULK3 and BRD4 to help people with newly diagnosed or treatment‑resistant multiple myeloma.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11233147

• New treatment approach for hard-to-treat multiple myeloma

  This study is testing a new treatment for multiple myeloma, especially to help African American patients who often face tougher challenges with the disease, by looking at how a special molecule can make current therapies work better against cancer cells that are hard to treat.

  NIH research Rowan University · Glassboro, United States · NIH-11074538

• Understanding how ULK3 affects multiple myeloma treatment resistance

  This study is looking at a protein called ULK3 to understand how it helps multiple myeloma cells survive and resist treatments, with the goal of creating new medicines that could work better for patients whose cancer is hard to treat.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-10979173

• New treatment approach for difficult-to-treat multiple myeloma

  This study is testing a new drug called KS18 that aims to help patients with multiple myeloma, especially those whose cancer hasn't responded to other treatments, by working alongside existing therapies to better fight the disease and prevent it from coming back.

  NIH research Rowan University · Glassboro, United States · NIH-10974902

Related topics

Quick answers

How many Refractory Multiple Myeloma clinical trials are recruiting right now?

25, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in United States (23 trials), China (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 10, Phase 2: 9, Phase 1/2: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →